OrthodontiCell, Inc. has secured sufficient capital to complete the remaining testing needed to support its application to begin a planned Phase II pivotal clinical study in the United States. The funding marks a critical step for the company as it advances a bioelectric technology intended to accelerate tooth movement during orthodontic treatment, potentially shortening treatment time and improving the patient experience when used alongside standard orthodontic care.
The significance of this development lies in what it enables: with testing funded, OrthodontiCell can now focus on completing the required studies and preparing its regulatory submission seeking authorization to initiate the planned final pivotal U.S. study. That proposed study is designed to evaluate the technology’s safety and effectiveness, including its potential to reduce the time required to straighten teeth. If successful, the technology could offer a new approach to orthodontic treatment that addresses one of the most common patient concerns—the length of time braces or aligners must be worn.
“For patients and families, a shorter path to a healthy, confident smile can make a meaningful difference,” said Mark Terrill, CEO of OrthodontiCell. “Securing the capital to complete this testing moves OrthodontiCell closer to its next clinical milestone and gives our team the resources to advance the application process.”
The capital secured covers the remaining testing supporting the planned application, though funding for conducting the pivotal study itself will be addressed separately. This distinction is important: while the current financing allows OrthodontiCell to complete the necessary preparatory work and file its regulatory submission, the larger costs of running the pivotal trial will require additional resources. Nevertheless, the company’s ability to secure this capital signals investor confidence in its bioelectric approach and its potential to disrupt the orthodontic market.
OrthodontiCell’s technology remains investigational. Initiation of the planned U.S. study is subject to completion of testing and applicable regulatory and ethics approvals. The company has stated that final study design, participating centers, and enrollment timing will be announced in the near future as the program advances. Statements concerning development plans, treatment benefits, and future milestones reflect current expectations; actual results and timing may differ.
For the orthodontic industry, the announcement highlights a growing interest in technologies that can improve treatment efficiency and patient satisfaction. If OrthodontiCell’s bioelectric stimulation proves safe and effective in reducing treatment duration, it could become a valuable adjunct to conventional orthodontics, benefiting both patients and providers. The completion of testing and the subsequent regulatory submission will be key milestones to watch as the company moves closer to its planned pivotal study.
